MedTrace Logo

Markers in Acute Pancreatitis-1

NCT05279079 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 175

Last updated 2026-02-19

No results posted yet for this study

Summary

Prospective, multi-national, multi-centre observational diagnostic study of novel microRNA and protein biomarkers in peripheral blood and/or urine to detect and predict the severity of drug-associated acute pancreatitis (AP), with comparison of the same biomarkers in patients with acute pancreatitis from other causes, chronic pancreatitis, pancreatic cancer, diabetes mellitus and healthy volunteers.

Conditions

  • Acute Pancreatitis Drug-Induced

Interventions

DIAGNOSTIC_TEST

Assessment of accuracy of microRNA and pancreatic enzyme markers in blood and/or urine in the detection and/or prediction of severity of drug-associated acute pancreatitis

Panel of microRNA and pancreatic enzyme biomarkers

Sponsors & Collaborators

  • Innovative Medicines Initiative

    collaborator OTHER

  • TransBioLine Consortium

    collaborator UNKNOWN

  • Liverpool University Hospitals NHS Foundation Trust

    collaborator OTHER_GOV

  • Klinikum der Universität München

    collaborator UNKNOWN

  • Hospital Regional de Malaga

    collaborator OTHER

  • University of Liverpool

    lead OTHER

Principal Investigators

  • Robert Sutton, MD FRCS PhD · University of Liverpool

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-01-25
Primary Completion
2025-01-31
Completion
2025-01-31

Countries

  • Germany
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05279079 on ClinicalTrials.gov